85666-15-5

Usage

Uses

Used in Pharmaceutical Industry:
IFLAB-BB F2108-0078 is used as an intermediate in the synthesis of various pharmaceuticals for its unique chemical structure and reactivity.
Used in Agrochemical Industry:
IFLAB-BB F2108-0078 is used as a building block in the development of agrochemicals to create effective and targeted products.
Used in Research and Development:
IFLAB-BB F2108-0078 is used as a valuable compound in research and development for exploring its potential applications and properties in various fields.
It is important to handle and store IFLAB-BB F2108-0078 with care, as it may pose risks to human health and the environment if not managed properly.

Upstream product

• 32361-76-5 3-(4'-nitrobenzyl)pyridine 

Downstream Products

• 75987-20-1 3-(4'-Hydroxybenzyl)pyridine 
• 1062139-48-3 ethyl (2E)-2-pentanoyl-3-{[4-(pyridin-3-ylmethyl)phenyl]amino}acrylate 
• 1062139-53-0 ethyl (2E)-2-(cyclopentylacetyl)-3-{[4-(pyridin-3-ylmethyl)phenyl]amino}acrylate 
• 874367-72-3 3-(4-bromobenzyl)pyridine 
• 85666-17-7 furegrelate sodium 
• 85666-43-9 3-bromo-2-hydroxy-5-(3-pyridylmethyl)benzaldehyde 
• 85666-04-2 3-(3-formyl-4-hydroxybenzyl)pyridine 
• 91874-36-1 2,8-Di(pyridin-3-yl)methyl-13-phenyl-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine 

Relevant academic research and scientific papers

Affinity of 3-acyl substituted 4-quinolones at the benzodiazepine site of GABAA receptors

The finding that alkyl 1,4-dihydro-4-oxoquinoline-3-carboxylate and N-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxamide derivatives may be high-affinity ligands at the benzodiazepine binding site of the GABAA receptor, prompted a study of 3-acyl-1,4-dihydro-4-oxoquinoline (3-acyl-4-quinolones). In general, the affinity of the 3-acyl derivatives was found to be comparable with the 3-carboxylate and the 3-carboxamide derivatives, and certain substituents (e.g., benzyl) in position 6 were again shown to be important. As it is believed that the benzodiazepine binding site is situated between an α- and a γ-subunit in the GABAA receptor, selected compounds were tested on the α1β2γ2s, α2β2γ2s and α3β2γ2s GABAA receptor subtypes. The 3-acyl-4-quinolones display various degrees of selectivity for α1- versus α2- and α3-containing receptors, and high-affinity ligands essentially selective for α1 over α3 were developed.

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Thromboxane A2 synthase inhibitors. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acids.

The synthesis and screening of a series of 5-(3-pyridylmethyl)benzofuran-2-carboxylic acids as selective thromboxane A2 (TxA2) synthase inhibitors is outlined. The ability of these compounds to inhibit TxA2 biosynthesis was assayed using microsomal enzyme

Pyridyl-substituted-benzofurans

The present invention provides novel pyridinyl-benzofurans and derivatives thereof which are useful as thromboxane A2 (TXA2) synthetase inhibitors and as such represent potent pharmacological agents.

Pyridyl-substituted-benzofurans

The present invention provides novel pyridinyl-benzofurans and derivatives thereof which are useful as thromboxane A2 (TXA2) synthetase inhibitors and as such represent potent pharmacological agents.